Haylee Brown

Haylee Brown is an associate in the firm’s Life Sciences group. Haylee’s practice covers all phases of the corporate life cycle, including startup and formation matters, venture financings and initial public offerings, with a focus on representing both public companies and investment banks in connection with a variety of capital markets transactions. Haylee also counsels clients on ongoing securities law compliance and corporate governance matters.

Haylee’s experience includes, among others, representation of:

• Scholar Rock Holding Corporation in its $300 million follow-on offering
• Underwriters in The Pennant Group, Inc.’s $124.7 million public offering
• The agents in multiple “at-the-market” transaction programs, including those of Sera Prognostics, Inc., and Inotiv, Inc.
• Underwriters in scPharmaceuticals Inc.’s $50 million follow-on public offering
• Underwriters in Lineage, Inc.’s $5.1 billion initial public offering
• Underwriters in Taysha Gene Therapies’ $75 million follow-on offering
• Underwriters in PACS Group, Inc.’s $450 Million IPO and their upsized $690 million primary and secondary follow-on offering
• Titan Partners Group in Aileron Therapeutics, Inc.’s $20 million registered direct offering
• Titan Partners Group in Reviva Pharmaceuticals Holdings, Inc.’s $5 million registered direct offering 
• Chardan Capital Markets LLC in Presto Automation Inc.’s $1.2 million registered direct offering
• Prime Medicine, Inc.’s $161 million follow-on offering
• Prime Medicine, Inc. in connection with its $300 million at-the-market offering
• Brainstorm Cell Therapeutics’ $7.5 Million registered direct offering
• Olink’s $80.75 million follow-on offering
• Initial Purchasers and Dealers in Enovis Corporation’s $460 million 3.875% convertible senior notes offering and capped call
• Arrowroot Capital Acquisition Corp. in its business combination with iLearningEngines 
• MBX Biosciences, Inc.’s $115 million Series B financing
• Ally Bridge Group in various investments, including Profound Bio
• Enspire DBS Therapy in its $17.6 million Series B financing